Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:

‍

Spencer Kimball reports that the U.S. Food and Drug Administration will decide on whether to fully approve Eisai and Biogen’s Alzheimer’s treatment Leqembi by July 6, 2023. (CNBC)

Dr. Emily Largent, of the University of Pennsylvania, examines ways of creating a better experience for those participating in Alzheimer’s clinical trials. (Being Patient)

At Yale School of Medicine, Jennifer Miller, PhD, associate professor of medicine and founder of Bioethics International, discusses the importance of diversity in clinical trials.

‍
‍

Our Culture

“I’ve been at the company over seven years, and it’s been really cool to watch the company grow and continue to increase how we help our clients. One of the many things I like about my job is that it’s not always the same thing every day, because each client is unique. It makes every day interesting.

Judi is a platform. It’s an adjudication tool, but it’s also more. It’s a whole collaborative workflow process tool. It works with DSMB, Eligibility, anything.”

   –Stephen, Lead Engineer

‍

‍‍
‍

About Judi

Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 171 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 certified collaboration platform.

‍